Immunogenicity of chimeric MUC۱-HER۲ vaccine against breast cancer in mice

Objective(s): Breast cancer is one of the most common cancers in the world and is on the increase. MUC۱ and HER۲ as tumor-associated antigens (TAAs) are abnormally expressed to some extent in ۷۵–۸۰% of breast cancers.  In our present research, a novel chimeric MUC۱-HER۲ (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis of the HER۲-MUC۱ construct confirmed the co-expression of MUC۱ and HER۲. Materials and Methods: BALB/c mice were immunized with this novel chimeric protein. The humoral immune response was assessed by enzyme-linked immunosorbent assay (ELISA). Then, BALB/c mice were injected subcutaneously ۲×۱۰۵ ۴T۱-MUC۱-HER۲ tumor cells. Subsequently, tumor size and tumor necrosis measurements, MTT, cytokines assay and survival test were performed.  Results: The results implied a critical role of HER۲ and MUC۱ antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer. Conclusion: The results implied a critical role of HER۲ and MUC۱ antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer.

کلیدواژه ها:

Breast Cancer ، HER۲ ، MUC۱ ، Recombinant antigen ، Vaccine